Akorn, Inc. (AKRX) Given Consensus Recommendation of “Hold” by Analysts
Akorn, Inc. (NASDAQ:AKRX) has been given an average recommendation of “Hold” by the twelve research firms that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation and eight have given a hold recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $30.83.
Several research analysts have recently weighed in on the company. William Blair restated a “hold” rating on shares of Akorn in a research note on Thursday. BidaskClub cut Akorn from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 22nd. Zacks Investment Research cut Akorn from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. Finally, Deutsche Bank set a $34.00 price objective on Akorn and gave the company a “hold” rating in a research report on Thursday, February 22nd.
In related news, major shareholder John N. Kapoor sold 13,629 shares of the company’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $32.67, for a total transaction of $445,259.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 28.20% of the stock is currently owned by corporate insiders.
Akorn (AKRX) traded down $1.04 during mid-day trading on Wednesday, hitting $17.93. The stock had a trading volume of 3,723,609 shares, compared to its average volume of 2,485,659. Akorn has a 52-week low of $16.79 and a 52-week high of $34.00. The company has a quick ratio of 3.19, a current ratio of 4.27 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $2,376.15, a PE ratio of 18.11, a P/E/G ratio of 0.71 and a beta of 1.78.
COPYRIGHT VIOLATION WARNING: “Akorn, Inc. (AKRX) Given Consensus Recommendation of “Hold” by Analysts” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/akorn-inc-akrx-given-consensus-recommendation-of-hold-by-analysts/1910107.html.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.